Literature DB >> 11015531

Visual field constriction in children with epilepsy on vigabatrin treatment.

P Iannetti1, A Spalice, F M Perla, E Conicella, U Raucci, B Bizzarri.   

Abstract

Vigabatrin is considered the drug of choice for infantile spasms and simple and complex partial epilepsy in childhood. Its mechanism of action relies on the irreversible inhibition of gamma-aminobutyric acid (GABA) transaminase. Since June 1997 several articles have been published reporting visual field constriction in adult patients on vigabatrin therapy. Recently, 7 pediatric patients, 1 on vigabatrin monotherapy and 6 on add-on therapy with visual field constriction have been described. We have observed 30 pediatric patients with epilepsy (14 boys and 16 girls), ages ranging from 4 to 20 years (mean: 11 years and 2 months) treated with vigabatrin for infantile spasms, simple and complex partial epilepsy, who had never complained of ophthalmologic disturbances. Twenty-one patients underwent complete routine ophthalmologic examination (fundus oculi, visual acuity, intraocular pressure, and visual field tests); 9 children (<6 years old) underwent only fundus examination, because collaboration was lacking. We report on 4 children showing constriction of visual field, prevailing in nasal hemifield. In 1 child, visual abnormalities were stable even 10 months after vigabatrin discontinuation, while in another a greater improvement was observed 5 months after discontinuation. The possible mechanisms have been discussed and the cone dysfunction, connected with GABA augmentation in the outer retina, has been outlined. We suggest a possible protocol to control visual abnormalities in epileptic children.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11015531     DOI: 10.1542/peds.106.4.838

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  10 in total

Review 1.  A risk-benefit assessment of treatments for infantile spasms.

Authors:  R Nabbout
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

Review 2.  Vigabatrin.

Authors:  James W Wheless; R Eugene Ramsay; Stephen D Collins
Journal:  Neurotherapeutics       Date:  2007-01       Impact factor: 7.620

Review 3.  The safety and tolerability of newer antiepileptic drugs in children and adolescents.

Authors:  Dean P Sarco; Blaise F D Bourgeois
Journal:  CNS Drugs       Date:  2010-05       Impact factor: 5.749

4.  Vigabatrin and visual field defects in pediatric epilepsy patients.

Authors:  Su Jeong You; HyoSook Ahn; Tae-Sung Ko
Journal:  J Korean Med Sci       Date:  2006-08       Impact factor: 2.153

5.  Clinical profile of vigabatrin as monotherapy for treatment of infantile spasms.

Authors:  Jason T Lerner; Noriko Salamon; Raman Sankar
Journal:  Neuropsychiatr Dis Treat       Date:  2010-11-08       Impact factor: 2.570

Review 6.  Molecular mechanisms of antiseizure drug activity at GABAA receptors.

Authors:  L John Greenfield
Journal:  Seizure       Date:  2013-05-14       Impact factor: 3.184

Review 7.  Treatment of partial seizures in childhood : an overview.

Authors:  Giangennaro Coppola
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

8.  Changes in the electroretinogram resulting from discontinuation of vigabatrin in children.

Authors:  Carol A Westall; Rita Nobile; Sharon Morong; J Raymond Buncic; William J Logan; Carole M Panton
Journal:  Doc Ophthalmol       Date:  2003-11       Impact factor: 2.379

Review 9.  Practice parameter: medical treatment of infantile spasms: report of the American Academy of Neurology and the Child Neurology Society.

Authors:  M T Mackay; S K Weiss; T Adams-Webber; S Ashwal; D Stephens; K Ballaban-Gill; T Z Baram; M Duchowny; D Hirtz; J M Pellock; W D Shields; S Shinnar; E Wyllie; O C Snead
Journal:  Neurology       Date:  2004-05-25       Impact factor: 9.910

10.  Current trends in the treatment of infantile spasms.

Authors:  Chang-Yong Tsao
Journal:  Neuropsychiatr Dis Treat       Date:  2009-05-20       Impact factor: 2.570

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.